Lepu Biopharma Co (HKSE:02157) Total Equity: HK$1,506 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02157 Lepu Biopharma Co Ltd HKSE:02157
44 GF Score
Price HK$4.60
GF Value HK$16.60
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Lepu Biopharma Co Total Equity?

Lepu Biopharma Co HKSE:02157 -1.18% 44 Total Equity is HK$1,506 Mil as of Dec. 2025. GuruFocus rates HKSE:02157 with a GF Score™ of 44/100 and a GF Value™ of HK$16.60 (Possible Value Trap). The stock has 6 warning signs investors should review.

Lepu Biopharma Co's total equity for the quarter that ended in Dec. 2025 was HK$1,506 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Lepu Biopharma Co Total Equity Historical Data

* Premium members only.

The historical data trend for Lepu Biopharma Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lepu Biopharma Co Total Equity Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 1,037.23 1,005.89 972.04 727.94 1,505.52

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 972.04 971.05 727.94 778.03 1,505.52
HKSE:02157
44GF Score
Lepu Biopharma Co Ltd HKSE:02157
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lepu Biopharma Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Lepu Biopharma Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3424.299-1918.775
=1,506

Lepu Biopharma Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3424.299-1918.775
=1,506

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$1,506 Mil mean?
Lepu Biopharma Co (HKSE:02157) has a Total Equity of HK$1,506 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Lepu Biopharma Co and its competitors.
Is Lepu Biopharma Co's Total Equity too high?
Lepu Biopharma Co's current Total Equity is HK$1,506 Mil. Overall, Lepu Biopharma Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's Total Equity compare to VRTX and REGN?
Lepu Biopharma Co's Total Equity of HK$1,506 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Lepu Biopharma Co and its competitors. Lepu Biopharma Co's current Total Equity is HK$1,506 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.60, compared to a current price of HK$4.60 — trading 72.3% below its estimated fair value. The current Total Equity is HK$1,506 Mil. Lepu Biopharma Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current Total Equity is HK$1,506 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?

Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued. The current stock price of HK$4.60 is trading 72.3% below its estimated GF Value™ of HK$16.60. GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.

Key valuation signals for HKSE:02157:

  • Total Equity: HK$1,506 Mil
  • GF Value™: HK$16.60 vs. price of HK$4.60 (72.3% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lepu Biopharma Co Business Description

Address Lianheng Road, Block 4, No. 651, Minhang District, Shanghai, CHN, 201112
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for HKSE:02157

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.60
Price
HK$16.60
GF Value